

THRU ONLINE FILING

March 27, 2024

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Sub: Press Release / Media Release

Dear Sir,

We are enclosing herewith the Press Release issued by the Company w.r.t Technology Transfer for development of an anti-cancer biosimilar for global market to M/s. Omexa Formulary Pvt. Ltd.

Thanking you.

Yours faithfully

For Ipca Laboratories Limited

Harish Kamath
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837



PRESS RELEASE

Mumbai, March 27, 2024: Ipca Laboratories Ltd. (Ipca) has entered into a Technology Transfer Agreement with Omexa Formulary Pvt. Ltd. (Omexa) for a biosimilar clone, process development and knowledge transfer for the global market. Under this Agreement, Ipca will grant to Omexa a non-exclusive right to research, develop, manufacture and market a anti-cancer biosimilar for global market.

This Agreement shall enable Omexa to develop this anti-cancer biosimilar from early stage of development to clinical trials and subsequent commercial launch. This agreement will also strengthen Omexa's capability of biosimilar development.

Commenting on this Agreement, Mr. Pranay Godha, Managing Director and CEO, Ipca Laboratories said "This collaboration with Omexa Formulary, an innovation driven and fast-growing biotech company, shall facilitate Omexa to build a solid foundation for potential anti-cancer and anti-inflammatory monoclonal antibody product development. This collaboration with Omexa in turn shall also help Ipca in the development and delivery of affordable and quality biologic medication for the treatment of chronic illnesses in the global market – a presently unmet and crucial clinical need. Ipca is committed to successfully develop quality and affordable biosimilars meeting global standards and gain a decisive edge in the battle against chronic ailments."

Commenting on this Agreement Dr. Nate Ramanathan, Managing Director & CEO of Omexa Formulary said "This collaboration with Ipca, a most reliable and trusted pharmaceutical company shall facilitate Omexa the availability of expertise and technology for the biosimilars development work and ensuring that Omexa play its part in serving our core values of affordable access to quality biologic drugs for a large population through our pioneering methods in R&D and manufacturing development."

About Ipca Laboratories Ltd.

Established in 1949, Ipca is a pharmaceutical company with a strong thrust on exports which now account for nearly 50% of company's income. Ipca is vertically integrated and produces finished dosage forms and active pharmaceutical ingredients. For more than 70 years, Ipca has been a crucial healthcare partner in over 120 countries across the globe.

Today, Ipca is one of the world's largest manufacturers and suppliers of over a dozen APIs. These APIs are produced from manufacturing facilities approved by the world's most discerning drug regulatory authorities like US – FDA, UK-MHRA, EDQM-Europe and WHO-Geneva, among others.

Ipca markets its branded formulations in India and rest of the world markets and generic formulations in United States, Europe, United Kingdom, Canada, Australia & New Zealand. APIs manufactured by Ipca are marketed across the globe.

Ipca is the 16th largest company in the Indian pharma market with leading brands in pain, rheumatology, anti-malarials and hair care therapy and 5 of its brands rank amongst the top 300 brands (IQVIA December 2023).



About Omexa Formulary Pvt. Ltd.

Omexa Formulary Private Limited is at the forefront of biosimilar innovation, dedicated to producing high-quality alternatives to brand-name biologics through scientific excellence, unwavering commitment and technological innovation. Omexa aims to empower healthcare providers and reach patients worldwide ensuring they receive dependable, effective and cost-efficient therapies.

Omexa's mission is to enhance patient access to vital treatments while ensuring safety, efficacy and affordability, through harnessing advanced technologies and rigorous scientific methodologies Omexa proposes to bridge the future of healthcare with today's needs. Omexa's vision is to be the global benchmark in biosimilar healthcare, where every patient has access to sustainable, state-of-the-art and affordable treatment, fostering a world where quality healthcare knows no boundaries.

Mr. Pranay Godha
Managing Director & CEO
Ipca Laboratories Ltd.

Dr. Nate Ramanathan
Managing Director & CEO
Omexa Formulary Pvt. Ltd.

FOR MORE INFORMATION

Ipca Laboratories Ltd
Sanjeev Gupta
Sr. VP, Biosimilar (ABL)
+91-9619730425
sanjeev.gupta@ipca.com

Omexa Formulary Pvt. Ltd.
Sudhir Puri
Sr. VP, Corporate Strategy
+91 9901199885
sudhir@omexa.in